Impact Factor 4.259 | CiteScore 4.30
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2019.01984

Bacteriophages reduce pathogenic Escherichia coli counts in mice without distorting gut microbiota

 Upuli A. Dissanayake1, 2, 3, Maria Ukhanova3, Zachary D. Moye4,  Alexander Sulakvelidze4 and  Volker Mai1, 2, 3*
  • 1University of Florida, United States
  • 2Department of Epidemiology, College of Public Health and Health Professions, University of Florida, United States
  • 3Emerging Pathogens Institute, University of Florida, United States
  • 4Intralytix (United States), United States

We performed a study to (i) investigate efficacy of an Escherichia coli/Salmonella spp./Listeria monocytogenes-targeting bacteriophage cocktail (tentatively named F.O.P.) to reduce a human pathogenic E. coli strain O157:H7 in experimentally infected mice, and (ii) determine how bacteriophages impact the normal gut microbiota when compared with antibiotic therapy. A total of 85 mice were inoculated with E. coli O157:H7 strain Ec231 (nalidixic acid resistant (NalAcR)) via oral gavage, and were randomized into six groups separated into three categories: 1st category received PBS or No phage/No PBS (control), 2nd category received either F.O.P., F.O.P. at 1:10 dilution, or the E. coli phage component of F.O.P (EcoShield PX™), and 3rd category received the antibiotic ampicillin. All therapies were administered twice daily for four consecutive days, except ampicillin which was administered twice on day zero before and after bacterial challenge. Fecal samples collected at Days 0, 1, 2, 3, 5, and 10. Samples were homogenized and plated on LB plates supplemented with NalAc to determine viable Ec231 counts. Individual weights were recorded at every fecal sample collection for trend analysis. qPCR was performed using specific E. coli primers to quantify the number of E. coli genome copies. Microbiota community profiles were analyzed using Denature Gradient Gel Electrophoresis (DGGE) and 16S rRNA sequencing. F.O.P. significantly (P< 0.05) reduced E. coli pathogen counts by more than 55% with a similar reduction observed with ampicillin therapy. Greater initial weight-loss occurred in mice treated with ampicillin (-5.44%) compared to other treatment groups. No notable changes in the gut microbiota profiles were observed for control and F.O.P. groups. In contrast, the antibiotic group displayed noticeable distortion of the gut microbiota composition, only partially returning to normal by Day 10. In conclusion, we found that F.O.P. administration was effective in reducing viable E. coli in infected mice with a similar efficacy to ampicillin therapy. However, the F.O.P. bacteriophage preparation had less impact on the gut microbiota compared to ampicillin.

Keywords: Bacteriophage (Phage), Bacteriophage, Phage, E.coli, Foodborne disease, microbiome

Received: 03 May 2019; Accepted: 13 Aug 2019.

Edited by:

Axel Cloeckaert, Institut National de la Recherche Agronomique (INRA), France

Reviewed by:

Cristobal Chaidez, Centro de Investigación en Alimentación y Desarrollo (CIAD), Mexico
Yihui Yuan, Wuhan Institute of Virology, Chinese Academy of Sciences, China  

Copyright: © 2019 Dissanayake, Ukhanova, Moye, Sulakvelidze and Mai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Volker Mai, Emerging Pathogens Institute, University of Florida, Gainesville, 32610, Florida, United States, vmai@ufl.edu